Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker) [21]

British Journal of Dermatology

Volumn 143, Issue 5, 2000, Pages 1121-1122

  Salim, A ^a   Emerson, R M ^a   Dalziel, K L ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; DAPSONE; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; MINOCYCLINE; PREDNISOLONE; RETINOID;

ACRODERMATITIS; AGED; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PUSTULAR PSORIASIS; VIRUS INFECTION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PSORIASIS; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS;

EID: 0033749344     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03878.x     Document Type: Letter

References (9)

1. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases
2. Acrodermatitis continua responding to cyclosporin therapy
3. Basiliximab, an interleukin-2 receptor monoclonal antibody. A new therapy for psoriasis?
4. The pathophysiology of psoriasis
5. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients
6. Randomised trial of Simulect versus placebo for control of acute cellular rejection in renal allograft recipients
7. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: A comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1
8. Prolonged action of a chimeric IL-2 receptor (CD 25) monoclonal antibody used in cadaveric renal transplantation
9. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center